Loading
Heart Failure Treatment and Management / Diabetes Treatment and Management · Review
International Journal of Medical & Pharmaceutical Sciences · July 6, 2026
A consensus or society position rather than new primary data.
This is a narrative review consolidating evidence on heart failure pharmacotherapy across the ejection fraction spectrum and the clinical pharmacist's role in bridging the guideline-to-practice gap. It identifies that despite modern therapeutic options, only a minority of eligible patients receive complete therapy within recommended timeframes, and reports that pharmacist-led titration, adherence support, and comorbidity management improve optimization rates.
Narrative review. Literature and guidelines addressing heart failure management across ejection fraction spectrum.. Intervention: Clinical pharmacist-led titration, adherence support, and comorbidity management in heart failure care..
Heart failure affects more than 64 million people worldwide Only a minority of eligible patients receive complete therapy within recommended timeframes Pharmacist-led titration, adherence support, and comorbidity management consistently improve optimization rates
Pharmacist-led titration, adherence support, and comorbidity management consistently improve optimization rates
The source did not state who this applies to in practice.
A narrative review synthesizing contemporary heart failure pharmacotherapy guidelines and defining the clinical pharmacist's organizational role in implementation, not a primary efficacy or safety trial.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Heart failure remains one of the most consequential chronic syndromes in clinical medicine, affecting more than 64 million people worldwide and imposing a rising burden as populations age. The therapeutic landscape has shifted dramatically since 2021, yet the translation of guideline evidence into bedside practice remains strikingly incomplete. Objective: This narrative review consolidates the contemporary pharmacotherapy of heart failure across the ejection fraction spectrum and defines the clinical pharmacist’s role in closing the persistent guideline-to-practice gap. Methods: Peer-reviewed literature, society guidelines, and landmark randomized trials published through early 2026 were identified through structured searches of PubMed, Scopus, and major cardiology society repositories, with emphasis on evidence reshaping practice since the 2021 European and 2022 American guidelines. Results: The four pillars of therapy now anchor management of reduced ejection fraction, while non-steroidal mineralocorticoid antagonists and incretin-based agents have extended evidence-based options into mildly reduced and preserved ejection fraction. Despite this, only a minority of eligible patients receive complete therapy within recommended timeframes. Pharmacist-led titration, adherence support, and comorbidity management consistently improve optimization rates. Conclusion: Realizing the promise of modern heart failure pharmacotherapy depends less on new molecules than on disciplined implementation. The clinical pharmacist is uniquely positioned to convert guideline knowledge into measurable patient benefit.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.